Status:
ENROLLING_BY_INVITATION
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Lead Sponsor:
Calibr, a division of Scripps Research
Conditions:
Relapsed/Refractory B-cell Lymphomas
Diffuse Large B-Cell Lymphoma (DLBCL)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
Detailed Description
Patients will be enrolled following either the completion or early termination/discontinuation from Study NCT04450069 or any protocol in which patients were administered CLBR001. Patients will begin t...
Eligibility Criteria
Inclusion
- All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable.
- Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Exclusion
- There are no specific exclusion criteria for this study
Key Trial Info
Start Date :
January 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2036
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04488354
Start Date
January 21 2021
End Date
August 1 2036
Last Update
January 10 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope National Medical Center
Duarte, California, United States, 91010
2
University of California at San Diego
San Diego, California, United States, 92093
3
University of Chicago
Chicago, Illinois, United States, 60637
4
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455